siRNA drug Leqvio (inclisiran) to lower cholesterol: Trends in Pharmacological Sciences
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran: Inclisiran for cholesterol lowering - ScienceDirect
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
2021 Peptides and Oligonucleotides Harvest | Encyclopedia MDPI
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Neue Therapieoptionen zur Lipidkontrolle // New therapy options for lipid control
Donovan/Green
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia | NEJM
The novel siRNA inclisiran and population health management - Walker - 2023 - Prescriber - Wiley Online Library
Inclisiran - an overview | ScienceDirect Topics
Advances in oligonucleotide drug delivery | Nature Reviews Drug Discovery
The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and effi
Dossier zur Nutzenbewertung gemäß § 35a SGB V
siRNA drug Leqvio (inclisiran) to lower cholesterol: Trends in Pharmacological Sciences
The current registered clinical studies on inclisiran (* recruiting... | Download Scientific Diagram
PDF] Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | Semantic Scholar
Therapeutic siRNA: state of the art | Signal Transduction and Targeted Therapy
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9 | SpringerLink
A) Simplified overview of mechanism of action by Inclisiran.... | Download Scientific Diagram
IJMS | Free Full-Text | Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
Inclisiran in lipid management: A Literature overview and future perspectives - ScienceDirect
Dossier zur Nutzenbewertung gemäß § 35a SGB V
Leqvio - 5333 - EPAR
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents - C Macchi, M Banach, A Corsini, CR Sirtori, N Ferri, M Ruscica, 2019
Frontiers | Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries